Top 10 Minimally Invasive Glaucoma Surgery Devices Companies to Watch Through 2030
Discover the Leaders Shaping the Future of Minimally Invasive Glaucoma Surgery Devices
Explore the latest market intelligence on the top 10 minimally invasive glaucoma surgery devices companies driving innovation, patient outcomes, and competitive growth through 2030. Backed by robust competitive analysis, this article spotlights manufacturers transforming the ophthalmic landscape — and provides a gateway to deeper insights in the Minimally Invasive Glaucoma Surgery Devices Market by Mechanism (Canaloplasty, Subconjunctival Filtration, Suprachoroidal Shunts), End User, Distribution Channel, Indication - Global Forecast 2025-2030 report.
1. Alcon Inc.
As a global ophthalmic leader, Alcon Inc. stands at the forefront of minimally invasive glaucoma surgery (MIGS) device innovation. The company’s comprehensive portfolio leverages advanced microincisional platforms, focusing on both canaloplasty and trabecular micro-bypass solutions. Alcon’s global distribution and robust R&D efforts ensure its continued leadership and strong presence across surgical centers and clinics worldwide.
2. Glaukos Corporation
Glaukos Corporation is recognized for pioneering the first FDA-approved trabecular micro-bypass stent and continues to drive clinical adoption of minimally invasive treatments. With a reputation for engineering precision and evidence-driven device design, Glaukos emphasizes targeted intraocular pressure management and novel microstent technologies, cementing its competitive advantage in both U.S. and international markets.
3. Johnson & Johnson Vision Care, Inc.
Johnson & Johnson Vision Care, Inc. is a major force in ophthalmic innovation, particularly with its development of MIGS devices tailored for multi-mechanistic approaches. The company blends advanced digital planning with surgeon-friendly implantation techniques, resulting in high adoption rates and sustained clinical impact across hospitals and ambulatory centers.
4. Santen Pharmaceutical Co., Ltd.
A specialist in ophthalmology, Santen Pharmaceutical Co., Ltd. leverages its deep clinical insights and global manufacturing expertise to advance subconjunctival filtration and suprachoroidal shunt technologies. Through dedicated collaboration with surgical experts and ongoing regulatory engagement, Santen is expanding access to next-generation MIGS across emerging and established markets.
5. Ivantis, Inc.
Renowned for its innovative Hydrus Microstent, Ivantis, Inc. focuses on novel canal-based interventions that deliver sustained intraocular pressure control. By targeting Schlemm’s canal and optimizing scaffold-based device designs, Ivantis continually enhances procedural outcomes and has cemented its role as a market trendsetter in the MIGS segment.
6. AbbVie Inc.
AbbVie Inc., through its dynamic ophthalmology division, advances competitive differentiation by integrating biocompatible coatings and proprietary materials into its MIGS devices. Its strategic acquisitions and broad clinical trial investments underscore its commitment to evidence-based innovation and expanding global reach within glaucoma surgery.
7. MicroSurgical Technology, Inc.
MicroSurgical Technology, Inc. specializes in precision-driven canaloplasty and microcatheter systems that cater to specialized procedural requirements. Its focus on surgeon training and continuous improvement delivers clinical reliability and positions the company as an agile partner for both high-volume centers and niche ophthalmic practices.
8. New World Medical, Inc.
With a foundation in innovative glaucoma solutions, New World Medical, Inc. excels in designing subconjunctival filtration implants tailored for long-term patency and ease of implantation. Its collaborative development approach and surgeon-focused support help accelerate the shift toward minimally invasive procedures, particularly in hospital and outpatient settings.
9. Oertli Instrumente AG
Based in Switzerland, Oertli Instrumente AG champions precision-engineered MIGS devices, seamlessly integrating with advanced surgical systems in ophthalmology. By prioritizing operational efficiency and reliable device ergonomics, Oertli consistently meets the evolving demands of ambulatory and clinical surgical environments across EMEA and Asia-Pacific.
10. Istar Medical S.A.
Istar Medical S.A. brings next-generation suprachoroidal shunt technology to the MIGS market, leveraging proprietary material science and unparalleled device biocompatibility. The company is recognized for its rapid clinical progress and strong R&D pipeline, offering new therapeutic avenues for patients with complex and refractory glaucoma.
Access Comprehensive Market Research & Competitive Insights
For granular competitive analysis, market trends, and forecasts through 2030, access the full Minimally Invasive Glaucoma Surgery Devices Market by Mechanism (Canaloplasty, Subconjunctival Filtration, Suprachoroidal Shunts), End User, Distribution Channel, Indication - Global Forecast 2025-2030 report for actionable intelligence and strategic market positioning.